Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00091286
First received: September 7, 2004
Last updated: November 13, 2010
Last verified: October 2007
  Purpose

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells.

PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with stage IIB, stage III, or stage IV colorectal cancer.


Condition Intervention
Colorectal Cancer
Biological: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Immunogenicity of Vaccination With HER-2/Neu and CEA Derived Synthetic Peptides With GM-CSF-in-Adjuvant, in Patients With Stage IIB, III, or IV Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Safety of the 4-peptide mixture if fewer than 33% of patients experience a dose-limiting toxicity at day 22 [ Designated as safety issue: Yes ]
  • Immunogenicity of the peptide mixture by Elispot assay at day 22 [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: March 2003
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Determine whether vaccination comprising HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 causes an immune response in patients with stage IIB, III, or IV colorectal cancer.
  • Determine the safety of this regimen in these patients.

OUTLINE: Patients receive vaccination comprising HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, and 15. On day 22, patients undergo removal of the lymph node into which the vaccination site drains to determine whether the immune system is responding to the vaccine.

PROJECTED ACCRUAL: A maximum of 15 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of colorectal cancer

    • Stage IIB, III, or IV disease
  • HLA-A2- or -A3-positive

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified

Hematopoietic

  • Absolute neutrophil count > 1,000/mm^3
  • Hemoglobin > 9 g/dL
  • Platelet count > 100,000/mm^3

Hepatic

  • Liver function tests ≤ 2.5 times upper limit of normal (ULN)

Renal

  • Creatinine ≤ 1.5 times ULN

Cardiovascular

  • No New York Heart Association class III or IV heart disease

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No known or suspected allergies to any component of the study drug
  • No active connective tissue disease requiring medications
  • No systemic autoimmune disease with visceral involvement
  • No uncontrolled diabetes
  • No other severe autoimmune disease
  • No medical contraindication or potential problem that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • More than 30 days since prior immunotherapy
  • More than 30 days since prior growth factors
  • More than 30 days since prior allergy shots
  • No prior vaccination with any study peptides for malignancy

Chemotherapy

  • More than 30 days since prior chemotherapy

Endocrine therapy

  • More than 30 days since prior steroids

Radiotherapy

  • More than 30 days since prior radiotherapy

Surgery

  • More than 30 days since prior surgery

Other

  • At least 30 days, but ≤ 24 months, since prior therapy for colorectal cancer
  • No concurrent illegal drug use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00091286

Locations
United States, Virginia
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
Investigators
Study Chair: Charles M. Friel, MD University of Virginia
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00091286     History of Changes
Other Study ID Numbers: CDR0000386177, UVACC-GI37, UVACC-23302, UVACC-HIC-9976
Study First Received: September 7, 2004
Last Updated: November 13, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent colon cancer
stage IIB colon cancer
stage IIIA colon cancer
stage IIIB colon cancer
stage IIIC colon cancer
stage IVA colon cancer
stage IVB colon cancer
recurrent rectal cancer
stage IIB rectal cancer
stage IIIA rectal cancer
stage IIIB rectal cancer
stage IIIC rectal cancer
stage IVA rectal cancer
stage IVB rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on August 28, 2014